Search clinical trials for: D930, D565

Total 62 results

Chong Kun Dang Pharmaceutical

Completed

The Pharmacokinetics of D565 and the Drug Effect of D565 on Pharmacokinetic Characteristics of D930

Healthy

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930

Glaucoma

Korea, Republic of
Chong Kun Dang Pharmaceutical

Unknown

Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily

Ocular Hypertension | Glaucoma, Primary Open Angle

Korea, Republic of
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Ocular Hypertension | Primary Open-angle Glaucoma

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

V930 First in Man (FIM) Study (V930-002)(COMPLETED)

Cancers Expressing HER-2 and/or CEA
VHsquared Ltd.

Completed

A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease (HarbOR)

Crohn's Disease

United States, Germany, Canada, Hungary, Poland, Serbia, United Kingdom, Netherlands, Ukraine, Austria, Norway, Slovakia, Czechia
VHsquared Ltd.

Completed

A First Time in Human Study in Healthy Volunteers and Patients

Crohn's Disease

United Kingdom
Chong Kun Dang Pharmaceutical

Unknown

Clinical Trial to Evaluate Pharmacokinetic Profiles and Safety Between CKD-385 and D935 in Healthy Volunteers

Hypertension

Korea, Republic of
Daiichi Sankyo Co., Ltd.
CMIC Co, Ltd. Japan

Completed

DS-5565 Phase III Study for Renal Impairment in Japanese Subjects

Diabetic Peripheral Neuropathic Pain | Post-herpetic Neuralgia

Japan
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375

Type2 Diabetes Mellitus

Korea, Republic of
Daiichi Sankyo Co., Ltd.
Quintiles, Inc.; CMIC Co, Ltd. Japan; Quintiles Malaysia Sdn. Bhd.

Completed

DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain

Diabetic Peripheral Neuropathic Pain

Japan
Daiichi Sankyo Co., Ltd.

Completed

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Diabetic Peripheral Neuropathic Pain

China
Daiichi Sankyo Co., Ltd.
Quintiles, Inc.; SRL Medisearch Inc.

Completed

DS-5565 Phase III Study for Post-herpetic Neuralgia

Post-Herpetic Neuralgia

Japan
Daiichi Sankyo, Inc.

Completed

An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia

Pain Associated With Fibromyalgia

Poland, Ukraine, Germany, Spain, United States, Austria, Portugal, Slovenia, Bulgaria, Romania, Serbia, Canada, Australia, Estonia, Russian Federation, New Zealand, Hungary, Denmark, Lithuania, Slovakia, South Africa, Latvia, Finland, Norwa... and more
Shire

Completed

A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.

Healthy Volunteers

United States
VHsquared Ltd.

Completed

Open-label V565 Target Engagement Study

Ulcerative Colitis

United Kingdom
MedImmune LLC

Completed

A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas

Gastrointestinal Adenocarcinomas

United States
Daiichi Sankyo Co., Ltd.

Completed

Study of Mirogabalin for Central Neuropathic Pain

Central Neuropathic Pain

Japan, Korea, Republic of, Taiwan
Merck Sharp & Dohme LLC
University of California, San Diego; Inovio Pharmaceuticals

Completed

A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001)

Healthy
Universitätsklinikum Hamburg-Eppendorf
Charite University, Berlin, Germany; University Hospital Muenster; RWTH Aachen... and other collaborators

Recruiting

German Stroke Registry - Endovascular Treatment (GSR-ET)

Acute Ischemic Stroke

Germany
Celgene

Terminated

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

Fibrosis | Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Lung Diseases, Interstitial | Interstitial Lung Disease

United States, Canada
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase 1 Study of OSI-930 in Cancer Patients

Advanced Solid Tumors

United States, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)

Cancer
Shire
Dyax Corp.

Completed

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Hereditary Angioedema (HAE)

United States, Canada, Germany, Italy, Jordan, Puerto Rico, United Kingdom
Shire

Completed

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

Hereditary Angioedema (HAE)

United States, Jordan, Italy
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-385 in Healthy Volunteers

Cardiovascular Diseases

Korea, Republic of
Zhengzhou Yuan

Recruiting

Registration of Acute Ischemic Stroke With Large and Medium-sized Vascular Occlusion in Southwest China(LMVOS) (LMVOS)

Acute Ischemic Stroke

China
Xuanwu Hospital, Beijing

Recruiting

XuanwuH Acute Ischemic Stroke Registry

Acute Ischemic Stroke

China
Shire

Completed

A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children (SPRING)

Hereditary Angioedema

United States, Canada, Germany, Hungary, Spain
Shire
Takeda Development Center Americas, Inc.

Withdrawn

Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia

COVID-19 Pneumonia
Xuanwu Hospital, Beijing

Not yet recruiting

Registry of Acute Ischemic Stroke With Large- or Medium-vessel Occlusion (LOMEVO)

Acute Ischemic Stroke

China
Celgene

Terminated

A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

Discoid Lupus

United States
Massachusetts General Hospital
American Cancer Society, Inc.

Terminated

Prevention of Delirium After Bone Marrow Transplantation

Delirium

United States
Amgen
MedImmune LLC

Terminated

A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer

GI Adenocarcinoma

Germany, Netherlands
Takeda

Completed

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

China
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers

Rheumatoid Arthritis

Korea, Republic of
Daiichi Sankyo, Inc.
Syneos Health

Completed

Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease

Fibromyalgia

Spain, United States, Poland, Bulgaria, South Africa, Hungary, Czechia, Romania
Fujian Medical University Union Hospital

Recruiting

Stem Cell Derived Exosomes in the Treatment of Melasma and Its Percutaneous Penetration

Melasma

China
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease (RAISE)

Sickle Cell Disease

United States
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Angioedema

United States, Spain, Netherlands, Hungary, Italy, Canada, Germany, France, Japan, Poland
Charite University, Berlin, Germany
Shire International GmbH

Active, not recruiting

Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS) (LANA-FXII)

Hereditary Autoinflammatory Disease

Germany
Shire
Dyax Corp.

Completed

A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

Hereditary Angioedema (HAE)

United States
United States Department of Agriculture (USDA)
University of Connecticut

Completed

Soy and Isoflavones Effect on Bone

Osteoporosis

United States
Daiichi Sankyo, Inc.

Completed

Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors

Advanced Solid Malignant Tumors | Advanced Ovarian Cancer

United States
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Angioedema

United States, France, Netherlands, Spain, Hungary, Italy, Canada, Poland, Japan, Germany
Shire

Completed

Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

Japan
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United States, Spain, Italy, Greece, United Kingdom, Argentina, Poland, Austria
Takeda
Shire; Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura (TTP)

China, United States, France, Japan, Poland, Germany, Austria, Spain, Italy, Switzerland, United Kingdom
Shire

Completed

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Hereditary Angioedema (HAE)

United States, United Kingdom, Germany, Canada, Italy, Jordan, Puerto Rico
Catharina Ziekenhuis Eindhoven

Completed

Platelet Function in Minimal Extracorporeal Circulation in CABG (ECCTEG)

Thrombocytopathy

Netherlands

Search clinical trials for: D930, D565

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations